CoChat
Sign Up
Cited by 12Inflammasome and immune disordersImmunodeficiency and Autoimmune DisordersImmune Response and Inflammation

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index; none of the 18 sources its claims cite is checked for support yet.

RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation

Open access
Doye, Anne, Chaintreuil, Paul, Lagresle-Peyrou, Chantal, Batistic, Ludovic, Marion, Valentine, Munro, Patrick, Loubatier, Celine, Chirara, Rayana, Sorel, Nataël, Bessot, Boris, Bronnec, Pauline, Contenti, Julie, Courjon, Johan, Giordanengo, Valerie, Jacquel, Arnaud, Barbry, Pascal, Couralet, Marie, Aladjidi, Nathalie, Fischer, Alain, Cavazzana, Marina, Mallebranche, Coralie, Visvikis, Orane, Kracker, Sven, Moshous, Despina, Verhoeyen, Els, Boyer, Laurent·2024·Journal of Experimental Medicine
DOI 10.1084/jem.20231562PMC PMC11363864
Open this paper in CoChat — free accountOpen PDF

Abstract

A growing number of patients presenting severe combined immunodeficiencies attributed to monoallelic RAC2 variants have been identified. The expression of the RHO GTPase RAC2 is restricted to the hematopoietic lineage. RAC2 variants have been described to cause immunodeficiencies associated with high frequency of infection, leukopenia, and autoinflammatory features. Here, we show that specific RAC2 activating mutations induce the NLRP3 inflammasome activation leading to the secretion of IL-1β and IL-18 from macrophages. This activation depends on the activation state of the RAC2 variant and is mediated by the downstream kinase PAK1. Inhibiting the RAC2–PAK1–NLRP3 inflammasome pathway might be considered as a potential treatment for these patients.

Overview

CoChat Summary

Written by AI from the paper’s full text.

TL;DR

RAC2 gain-of-function variants associated with inborn errors of immunity activate the NLRP3 inflammasome through a RAC2–PAK1–NLRP3 signaling axis. This activation is detectable in patient circulating myeloid cells and primary macrophages and is blocked by PAK, NLRP3, or caspase inhibitors.

Key findings

  • RAC2 Q61R, E62K, D63V, G12R, G12V, and A59S bound GST–PAK–RBD and triggered pro-IL-1β cleavage/IL-1β secretion in an HEK293T NLRP3 reconstitution system; the inhibitory D57N variant behaved like empty vector and lower than WT RAC2.
  • In a RAC2 E62K patient, caspase-1 activity was increased in monocytes and granulocytes but not lymphocytes; up to 12% of monocytes had caspase-1 specks versus a mean of 4% in controls. In RAC2 A59S and E62K patient monocytes, 11.4% and 14.3% of cells had FAM–YVAD–FLICA-positive specks, respectively, versus 4% in controls.
  • IPA3, AZ13711265, MCC950, and Emricasan blocked IL-1β secretion triggered by gain-of-function RAC2 variants Q61R, E62K, D63V, and G12R. NLRP3 T659A impaired IL-1β secretion, GSDMD knockout impaired it, NINJ1 knockout did not affect it, and no significant cell death was measured.
  • Primary human macrophages overexpressing gain-of-function variants secreted higher IL-1β and IL-18; MOLM-13 cells expressing RAC2 E62K showed an increased IL-1β cytokine-related gene signature; single-cell RNAseq of a RAC2 A59S patient showed increased NLRP3 and IL-1β expression in monocytes and myeloid dendritic cells.

Methods

  • Mechanistic assays used HEK293T cells transfected with NLRP3 inflammasome components (myc-NLRP3, ASC-GFP, caspase-1, pro-IL-1β-Flag) plus HA-RAC2 WT or mutants, GST–PAK–RBD pull-down, immunoblotting, and pathway inhibitors.
  • Patient and primary-cell assays used whole blood/PBMCs from healthy donors and RAC2 E62K or A59S patients, flow cytometry with FAM–YVAD–FLICA for caspase-1 activity/specks, monocyte-derived macrophages transduced with lentiviral RAC2 variants and stimulated with LPS, ELISA for IL-1β/IL-18, immunofluorescence for ASC/NLRP3, U937 knockout lines, and LDH release.
  • Transcriptomic analyses included bulk RNAseq of MOLM-13 cells transduced with RAC2 WT or E62K versus empty vector, and single-cell RNAseq of whole blood from one RAC2 A59S patient and a control (8,078 control cells, 14,524 patient cells).

Limitations

  • The paper states that RAC2 variants are rare, mostly found in young children with low leukocyte counts, which limits more precise immunophenotyping with pyroptotic cell death markers; it also states that further studies are needed to determine the contribution of the inflammasome pathway to RAC2 gain-of-function disease and whether NLRP3 is a treatment target.
  • Evident from the text: key patient data come from very few individuals (one RAC2 E62K and one RAC2 A59S patient in central assays), while many mechanistic conclusions rely on overexpression or reconstitution systems rather than in vivo models of RAC2-mutant disease.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1084/jem.20231562

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. RAC2 Q61R, RAC2 D63V, RAC2 E62K, and RAC2 G12R mutants bind PAK1 RBD. Hemagglutinin-tagged RAC2 (WT) and mutants were expressed for 16 h in HEK293T cells. HA-RAC2 activation level measurements were assessed by GST–PAK–RBD pull-down assay followed by immunoblotting (IB). (A) RAC2 Q61R mutation was compared with WT and the constitutively active mutant RAC2 Q61E. (B) D57N, D63V, and E62K mutations were compared with WT and the constitutively active mutant RAC2 Q61E. (C) RAC2 G12R mutation was compared with WT and the constitutively active mutants RAC2 G12V and RAC2 Q61E. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. Source data are available for this figure: SourceData F1.
Figure 1. RAC2 Q61R, RAC2 D63V, RAC2 E62K, and RAC2 G12R mutants bind PAK1 RBD. Hemagglutinin-tagged RAC2 (WT) and mutants were expressed for 16 h in HEK293T cells. HA-RAC2 activation level measurements were assessed by GST–PAK–RBD pull-down assay followed by immunoblotting (IB). (A) RAC2 Q61R mutation was compared with WT and the constitutively active mutant RAC2 Q61E. (B) D57N, D63V, and E62K mutations were compared with WT and the constitutively active mutant RAC2 Q61E. (C) RAC2 G12R mutation was compared with WT and the constitutively active mutants RAC2 G12V and RAC2 Q61E. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. Source data are available for this figure: SourceData F1.CC BY-NC-SA · PubMed Central
Figure 2. NLRP3 inflammasome activation is correlated to RAC2 activation level. HEK293T cells were transfected for 16 h with plasmids encoding the NLRP3 inflammasome components: myc-NLRP3, GFP-tagged ASC, mouse Caspase-1 (mCaspase1), and pro-IL-1β-Flag together with the WT form or the different mutants of RAC2 (HA-RAC2). Cleaved-IL-1β secretion in the culture supernatant (Sup) and protein expression in the cell lysates were assessed by immunoblotting. (A) RAC2 Q61R mutation was compared with WT and the constitutively active mutant RAC2 Q61E. (B) RAC2 D57N, D63V, and E62K mutations were compared with WT and the constitutively active mutant RAC2 Q61E. (C) G12R mutation was compared to WT and the constitutively active mutant RAC2 G12V. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. Source data are available for this figure: SourceData F2.
Figure 2. NLRP3 inflammasome activation is correlated to RAC2 activation level. HEK293T cells were transfected for 16 h with plasmids encoding the NLRP3 inflammasome components: myc-NLRP3, GFP-tagged ASC, mouse Caspase-1 (mCaspase1), and pro-IL-1β-Flag together with the WT form or the different mutants of RAC2 (HA-RAC2). Cleaved-IL-1β secretion in the culture supernatant (Sup) and protein expression in the cell lysates were assessed by immunoblotting. (A) RAC2 Q61R mutation was compared with WT and the constitutively active mutant RAC2 Q61E. (B) RAC2 D57N, D63V, and E62K mutations were compared with WT and the constitutively active mutant RAC2 Q61E. (C) G12R mutation was compared to WT and the constitutively active mutant RAC2 G12V. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. Source data are available for this figure: SourceData F2.CC BY-NC-SA · PubMed Central
Figure 3. NLRP3 inflammasome activation induced by RAC2 active mutants is inhibited by inhibitors of the PAK–NLRP3 inflammasome signaling pathway. (A–F) HEK293T cells were transfected for 16 h with plasmids encoding the NLRP3 inflammasome components (Inflam. mix) together with the HA-RAC2 Q61E (A), HA-RAC2 Q61R (B), HA-RAC2 E62K (C), HA-RAC2 D63V (D), HA-RAC2 G12R (E), or HA-RAC2 G12V (F). Inhibitors of NLRP3 (MCC950), PAK (IPA3 and AZ13711265), or pan-Caspases (Emricasan) were added 6 h before transfection. Cleaved-IL-1β secretion in the culture supernatant (Sup) and protein expression in the cell lysates were assessed by immunoblotting. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. Source data are available for this figure: SourceData F3.
Figure 3. NLRP3 inflammasome activation induced by RAC2 active mutants is inhibited by inhibitors of the PAK–NLRP3 inflammasome signaling pathway. (A–F) HEK293T cells were transfected for 16 h with plasmids encoding the NLRP3 inflammasome components (Inflam. mix) together with the HA-RAC2 Q61E (A), HA-RAC2 Q61R (B), HA-RAC2 E62K (C), HA-RAC2 D63V (D), HA-RAC2 G12R (E), or HA-RAC2 G12V (F). Inhibitors of NLRP3 (MCC950), PAK (IPA3 and AZ13711265), or pan-Caspases (Emricasan) were added 6 h before transfection. Cleaved-IL-1β secretion in the culture supernatant (Sup) and protein expression in the cell lysates were assessed by immunoblotting. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. Source data are available for this figure: SourceData F3.CC BY-NC-SA · PubMed Central
Figure 4. Caspase-1 activation triggered by RAC2 active variants in circulating myeloid cells and primary human monocyte–derived macrophages. (A–E) Whole blood circulating leukocytes from healthy donors (Control) or patient RAC2 E62K variant were incubated with the FAM–YVAD–FLICA probe for 1 h before fluorescent antibodies staining and analyzed by flow cytometry. CD14+ monocytes and CD66b+ granulocytes were gated as well as cells with low expression of CD14, CD66b, and CD16, corresponding to lymphocytes. Cells were analyzed for (A and B) FAM–YVAD–FLICA probe MFI or (C and D) for the presence of active Caspase-1 specks using Caspase-1-A and Caspase-1-H ratio analysis. Cells with Caspase-1 specks were defined by a high Caspase-1-A/Caspase-1-H ratio. Control conditions were repeated at least three times, and representative data are shown. (A) Overlay of the FAM–YVAD–FLICA fluorescence intensity measured in monocytes, granulocytes, and lymphocytes of healthy donors (Control) and patient variant RAC2 E62K. (B) Quantification of the FAM–YVAD–FLICA MFI measured in monocytes (Mo), granulocytes (Gr), and lymphocytes (Ly) of healthy donors (Control) and patient variant RAC2 E62K. Control conditions were repeated at least three times, and representative data are shown. (C and D) Gating of the monocytes and granulocytes with speck in healthy donors (Control) and patient variant RAC2 E62K using Caspase-1-A and Caspase-1-H ratio. (E) Graphic representation of the percentage of monocytes and granulocytes with Caspase-1 specks defined by a high Caspase-1-A/Caspase-1-H ratio in healthy donors (Control) and patient variant RAC2 E62K. (F and G) Human monocyte–derived macrophages were cotransduced for 72 h with Vpx containing virus-like particles and HA-tagged WT and mutated RAC2 encoding lentiviral vectors. Empty HIVSFFV-HARAC2-IRES-GFP vector (EV) was used as control. LPS was added for 8 h to induce the expression of pro-IL-1β. (F and G) Supernatants were analyzed using ELISA for (F) IL-1β and (G) IL-18. Data are mean ± SEM. Statistical analyses were performed using ordinary one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are representative for n = 3. (H) Volcano plot depicting differentially expressed genes in MOLM-13 transduced with RAC2 WT or RAC2 E62K compared to MOLM-13 transduced with empty vector. Red dots represent genes expressed at higher levels while blue dots represent genes with higher expression levels. Y axis denotes −log10 P values, and x axis shows log2 fold change values. Volcano plots were generated using VolcaNoseR. Data are representative for n = 5.
Figure 4. Caspase-1 activation triggered by RAC2 active variants in circulating myeloid cells and primary human monocyte–derived macrophages. (A–E) Whole blood circulating leukocytes from healthy donors (Control) or patient RAC2 E62K variant were incubated with the FAM–YVAD–FLICA probe for 1 h before fluorescent antibodies staining and analyzed by flow cytometry. CD14+ monocytes and CD66b+ granulocytes were gated as well as cells with low expression of CD14, CD66b, and CD16, corresponding to lymphocytes. Cells were analyzed for (A and B) FAM–YVAD–FLICA probe MFI or (C and D) for the presence of active Caspase-1 specks using Caspase-1-A and Caspase-1-H ratio analysis. Cells with Caspase-1 specks were defined by a high Caspase-1-A/Caspase-1-H ratio. Control conditions were repeated at least three times, and representative data are shown. (A) Overlay of the FAM–YVAD–FLICA fluorescence intensity measured in monocytes, granulocytes, and lymphocytes of healthy donors (Control) and patient variant RAC2 E62K. (B) Quantification of the FAM–YVAD–FLICA MFI measured in monocytes (Mo), granulocytes (Gr), and lymphocytes (Ly) of healthy donors (Control) and patient variant RAC2 E62K. Control conditions were repeated at least three times, and representative data are shown. (C and D) Gating of the monocytes and granulocytes with speck in healthy donors (Control) and patient variant RAC2 E62K using Caspase-1-A and Caspase-1-H ratio. (E) Graphic representation of the percentage of monocytes and granulocytes with Caspase-1 specks defined by a high Caspase-1-A/Caspase-1-H ratio in healthy donors (Control) and patient variant RAC2 E62K. (F and G) Human monocyte–derived macrophages were cotransduced for 72 h with Vpx containing virus-like particles and HA-tagged WT and mutated RAC2 encoding lentiviral vectors. Empty HIVSFFV-HARAC2-IRES-GFP vector (EV) was used as control. LPS was added for 8 h to induce the expression of pro-IL-1β. (F and G) Supernatants were analyzed using ELISA for (F) IL-1β and (G) IL-18. Data are mean ± SEM. Statistical analyses were performed using ordinary one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are representative for n = 3. (H) Volcano plot depicting differentially expressed genes in MOLM-13 transduced with RAC2 WT or RAC2 E62K compared to MOLM-13 transduced with empty vector. Red dots represent genes expressed at higher levels while blue dots represent genes with higher expression levels. Y axis denotes −log10 P values, and x axis shows log2 fold change values. Volcano plots were generated using VolcaNoseR. Data are representative for n = 5.CC BY-NC-SA · PubMed Central
Figure S1. Gating strategies and validation of protocol. (A) PBMCs isolated from healthy donors were treated for 1 h with FAM–YVAD–FLICA before CD14 labeling and then analyzed by flow cytometry. Live cells were gated and doublets were excluded using SSC-A and SSC-H plot. CD14 high monocytes were analyzed for the presence of Caspase-1 speck using FITC-Caspase-1-A and FITC-Caspase-1-H. Monocytes with Caspase-1 specks were defined by a high Caspase-1-A/Caspase-1-H ratio. (B) PBMCs were treated 8 h with LPS (100 ng/ml) and 1 h with Nigericin (5 µM) (LPS + Nigericin) or with vehicle (Control). After 1 h incubation with the FAM–YVAD–FLICA probe cells were CD14 labeled and analyzed by flow cytometry. Experiments were repeated at least four times and representative data are shown. (A and B) The data were reused from Fig. 6 A. (C) Graphic representation showing the percentage of cells with Caspase-1 speck. (D) Overlay of the FAM–YVAD–FLICA fluorescence intensity measured in monocytes healthy donors (Control) and cells treated with LPS and Nigericin (LPS + Nigericin). (E) Graphic representation of data showing the MFI measured. Data are expressed as the mean ± SEM. Statistical analyses were performed using paired t test. *P < 0.05. Data are representative for n = 3.
Figure S1. Gating strategies and validation of protocol. (A) PBMCs isolated from healthy donors were treated for 1 h with FAM–YVAD–FLICA before CD14 labeling and then analyzed by flow cytometry. Live cells were gated and doublets were excluded using SSC-A and SSC-H plot. CD14 high monocytes were analyzed for the presence of Caspase-1 speck using FITC-Caspase-1-A and FITC-Caspase-1-H. Monocytes with Caspase-1 specks were defined by a high Caspase-1-A/Caspase-1-H ratio. (B) PBMCs were treated 8 h with LPS (100 ng/ml) and 1 h with Nigericin (5 µM) (LPS + Nigericin) or with vehicle (Control). After 1 h incubation with the FAM–YVAD–FLICA probe cells were CD14 labeled and analyzed by flow cytometry. Experiments were repeated at least four times and representative data are shown. (A and B) The data were reused from Fig. 6 A. (C) Graphic representation showing the percentage of cells with Caspase-1 speck. (D) Overlay of the FAM–YVAD–FLICA fluorescence intensity measured in monocytes healthy donors (Control) and cells treated with LPS and Nigericin (LPS + Nigericin). (E) Graphic representation of data showing the MFI measured. Data are expressed as the mean ± SEM. Statistical analyses were performed using paired t test. *P < 0.05. Data are representative for n = 3.CC BY-NC-SA · PubMed Central
Figure 5. The RAC2 A59S human patient mutation activates the NLRP3 inflammasome. (A) HA-RAC2 (WT), HA-RAC2 A59S, and HA-RAC2 E62K mutants were expressed for 16 h in HEK293T cells. HA-RAC2 activation level measurements were assessed by GST–PAK–RBD pull-down assays and immunoblotting (IB). (B–E) HEK293T cells were transfected for 16 h with plasmids encoding the NLRP3 inflammasome components (Inflam. mix) together with the WT or RAC2 E62K or RAC2 A59S forms. Cleaved IL-1β secretion in the culture supernatant (Sup) and protein expression in the cell lysates were assessed by immunoblotting. (C) Inhibitors of NLRP3 (MCC950), PAK (IPA3 or AZ 13711265), or pan-Caspases (Emricasan) were added 6 h before transfection. Data are representative for n = 3. (D and E) Inflammasome was reconstituted in HEK293T to evaluate the effect of the NLRP3 T659A mutation on IL-1β secretion compared to NLRP3 in cells expressing (D) RAC2 A59S or (E) RAC2 E62K. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. (F) U937 Cas9 (Cas9), NLRP3 KO, or GSDMD KO cells were cotransduced for 72 h with Vpx containing virus-like particles and HA-tagged RAC2 A59S or E62K encoding lentiviral vectors. Empty HIVSFFV-HARAC2-IRES-GFP vector was used as control. LPS was added for 8 h to induce the expression of pro-IL-1β. Supernatants were analyzed using ELISA for IL-1β. Data are mean ± SEM. Statistical analyses were performed using two-way ANOVA. ****P < 0.0001. Data are representative for n = 3. (G) LDH release was measured in the culture medium of U937 Cas9 (Cas9), NLRP3 KO, or NINJ1 KO cells expressing empty vector (Control), HA-tagged RAC2 A59S, or RAC2 E62K. The graph represents the percentage of cytotoxicity. Data are representative for n = 3. (H) Single-cell analysis for a blood sample of a patient harboring a RAC2 A59S variant and a representative control healthy donor blood sample drawn at the same time and analyzed in parallel are shown. Uniform Manifold Approximation and Projection plots of whole blood cells from control and RAC2 A59S patient donors. After alignment, joint clustering allows to detect 13 cell populations. pDC, plasmacytoid dendritic cell; mDC, myeloid dendritic cell; ISG, IFN-stimulated genes. (I) Violin plots showing the distribution of gene expression of IL-1β and NLRP3 genes in the cell clusters for both control (red) and RAC2 A59S patient (blue). NKT, natural killer T. Source data are available for this figure: SourceData F5.
Figure 5. The RAC2 A59S human patient mutation activates the NLRP3 inflammasome. (A) HA-RAC2 (WT), HA-RAC2 A59S, and HA-RAC2 E62K mutants were expressed for 16 h in HEK293T cells. HA-RAC2 activation level measurements were assessed by GST–PAK–RBD pull-down assays and immunoblotting (IB). (B–E) HEK293T cells were transfected for 16 h with plasmids encoding the NLRP3 inflammasome components (Inflam. mix) together with the WT or RAC2 E62K or RAC2 A59S forms. Cleaved IL-1β secretion in the culture supernatant (Sup) and protein expression in the cell lysates were assessed by immunoblotting. (C) Inhibitors of NLRP3 (MCC950), PAK (IPA3 or AZ 13711265), or pan-Caspases (Emricasan) were added 6 h before transfection. Data are representative for n = 3. (D and E) Inflammasome was reconstituted in HEK293T to evaluate the effect of the NLRP3 T659A mutation on IL-1β secretion compared to NLRP3 in cells expressing (D) RAC2 A59S or (E) RAC2 E62K. Data are representative for n = 3. Molecular weight (kD) is indicated in the figure. (F) U937 Cas9 (Cas9), NLRP3 KO, or GSDMD KO cells were cotransduced for 72 h with Vpx containing virus-like particles and HA-tagged RAC2 A59S or E62K encoding lentiviral vectors. Empty HIVSFFV-HARAC2-IRES-GFP vector was used as control. LPS was added for 8 h to induce the expression of pro-IL-1β. Supernatants were analyzed using ELISA for IL-1β. Data are mean ± SEM. Statistical analyses were performed using two-way ANOVA. ****P < 0.0001. Data are representative for n = 3. (G) LDH release was measured in the culture medium of U937 Cas9 (Cas9), NLRP3 KO, or NINJ1 KO cells expressing empty vector (Control), HA-tagged RAC2 A59S, or RAC2 E62K. The graph represents the percentage of cytotoxicity. Data are representative for n = 3. (H) Single-cell analysis for a blood sample of a patient harboring a RAC2 A59S variant and a representative control healthy donor blood sample drawn at the same time and analyzed in parallel are shown. Uniform Manifold Approximation and Projection plots of whole blood cells from control and RAC2 A59S patient donors. After alignment, joint clustering allows to detect 13 cell populations. pDC, plasmacytoid dendritic cell; mDC, myeloid dendritic cell; ISG, IFN-stimulated genes. (I) Violin plots showing the distribution of gene expression of IL-1β and NLRP3 genes in the cell clusters for both control (red) and RAC2 A59S patient (blue). NKT, natural killer T. Source data are available for this figure: SourceData F5.CC BY-NC-SA · PubMed Central
Figure S2. Rac2 A59S– and E62K–triggered IL-1β secretion is GSDMD dependent. (A) U937 NINJ1 KO cells expressing empty vector (Control), HA-RAC2 A59S, or HA-RAC2 E62K were treated with LPS for 8 h to induce the expression of pro-IL-1β. Supernatants were analyzed using ELISA for IL-1β. Data are mean ± SEM. Statistical analyses were performed using ordinary one-way ANOVA. ***P < 0.001; ****P < 0.0001. Data are representative for n = 3. (B) LDH release was measured in the culture medium of U937 GSDMD KO cells expressing empty vector (Control) or HA-tagged RAC2 A59S or RAC2 E62K. The graph represents the percentage of cytotoxicity. Data are representative for n = 3.
Figure S2. Rac2 A59S– and E62K–triggered IL-1β secretion is GSDMD dependent. (A) U937 NINJ1 KO cells expressing empty vector (Control), HA-RAC2 A59S, or HA-RAC2 E62K were treated with LPS for 8 h to induce the expression of pro-IL-1β. Supernatants were analyzed using ELISA for IL-1β. Data are mean ± SEM. Statistical analyses were performed using ordinary one-way ANOVA. ***P < 0.001; ****P < 0.0001. Data are representative for n = 3. (B) LDH release was measured in the culture medium of U937 GSDMD KO cells expressing empty vector (Control) or HA-tagged RAC2 A59S or RAC2 E62K. The graph represents the percentage of cytotoxicity. Data are representative for n = 3.CC BY-NC-SA · PubMed Central
Figure S3. RAC2 A59S variant patients have increased circulating monocytes and dendritic cells. Point-range plot of the analysis of the difference of cell proportions in clusters between control and RAC2 A59S patient samples identified in single-cell RNAseq. NKT, natural killer T; ISG, IFN-stimulated gene; FDR, false discovery rate.
Figure S3. RAC2 A59S variant patients have increased circulating monocytes and dendritic cells. Point-range plot of the analysis of the difference of cell proportions in clusters between control and RAC2 A59S patient samples identified in single-cell RNAseq. NKT, natural killer T; ISG, IFN-stimulated gene; FDR, false discovery rate.CC BY-NC-SA · PubMed Central
Figure 6. Monocytes and macrophages isolated from patients harboring the RAC2 E62K or RAC2 A59S mutations have an abnormal NLRP3 inflammasome activation. (A) PBMCs isolated from healthy donors (Control) or patients with RAC2 mutation (RAC2 A59S and RAC2 E62K) were treated for 1 h with FAM–YVAD–FLICA before CD14 labeling and then analyzed by flow cytometry. Cells with high expression of CD14, corresponding to monocytes, were gated and then analyzed for the presence of Caspase-1 speck using FITC-Caspase-1-A and FITC-Caspase-1-H. Monocytes with Caspase-1 speck were defined by a high Caspase-1-A/Caspase-1-H ratio. Control conditions were repeated at least three times, and representative data are shown. (B and C) Graphic representation of percentage of cells with Caspase-1 specks. Control conditions are expressed as the mean ± SEM of at least three independent experiments. (D) Monocyte-derived macrophages isolated from control healthy donors or patients presenting RAC2 A59S or RAC2 E62K variants were stained with anti-ASC (green), anti-NLRP3 (red), Hoechst 33342 for nuclei (blue), and phalloidin-Alexa 647 for actin filaments (magenta). The arrow indicates ASC speck colocalization with NLRP3 staining. Scale bar represents 10 µm. (E and F) Monocyte-derived macrophages isolated from patient RAC2 A59S (E) or a RAC2 E62K (F) variants were treated with LPS alone or LPS and MCC950 for 8 h to induce the expression of IL-1β in the absence or presence of NLRP3 inhibition, respectively. Non-treated cells (NT) were used as control. IL-1β secretion was measured using ELISA. The data were reused in Fig. S1, A and B, to illustrate the gating strategy. Data are mean ± SEM. Data are representative for n = 2.
Figure 6. Monocytes and macrophages isolated from patients harboring the RAC2 E62K or RAC2 A59S mutations have an abnormal NLRP3 inflammasome activation. (A) PBMCs isolated from healthy donors (Control) or patients with RAC2 mutation (RAC2 A59S and RAC2 E62K) were treated for 1 h with FAM–YVAD–FLICA before CD14 labeling and then analyzed by flow cytometry. Cells with high expression of CD14, corresponding to monocytes, were gated and then analyzed for the presence of Caspase-1 speck using FITC-Caspase-1-A and FITC-Caspase-1-H. Monocytes with Caspase-1 speck were defined by a high Caspase-1-A/Caspase-1-H ratio. Control conditions were repeated at least three times, and representative data are shown. (B and C) Graphic representation of percentage of cells with Caspase-1 specks. Control conditions are expressed as the mean ± SEM of at least three independent experiments. (D) Monocyte-derived macrophages isolated from control healthy donors or patients presenting RAC2 A59S or RAC2 E62K variants were stained with anti-ASC (green), anti-NLRP3 (red), Hoechst 33342 for nuclei (blue), and phalloidin-Alexa 647 for actin filaments (magenta). The arrow indicates ASC speck colocalization with NLRP3 staining. Scale bar represents 10 µm. (E and F) Monocyte-derived macrophages isolated from patient RAC2 A59S (E) or a RAC2 E62K (F) variants were treated with LPS alone or LPS and MCC950 for 8 h to induce the expression of IL-1β in the absence or presence of NLRP3 inhibition, respectively. Non-treated cells (NT) were used as control. IL-1β secretion was measured using ELISA. The data were reused in Fig. S1, A and B, to illustrate the gating strategy. Data are mean ± SEM. Data are representative for n = 2.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

38 Own result · 20 Own method · 7 Own interpretation · 6 No full text of the sources · 4 Check pending · 2 Not checked yet · 1 Sources not found

  • It may state two separate claims as one. 20
  • The quote only partly states this claim. 11
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Create a free account to see these assumptions.

36 more claims

Create a free account to see all 78 claims and to verify the 7 references still open.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Cited by

See all 12

Related

See all

Metadata

Authors
Doye, A., Chaintreuil, P., Lagresle-Peyrou, C., Batistic, L., Marion, V., Munro, P., Loubatier, C., Chirara, R., Sorel, N., Bessot, B., Bronnec, P., Contenti, J., Courjon, J., Giordanengo, V., Jacquel, A., Barbry, P., Couralet, M., Aladjidi, N., Fischer, A., Cavazzana, M., Mallebranche, C., Visvikis, O., Kracker, S., Moshous, D., Verhoeyen, E., & Boyer, L.
Affiliations
  • Inserm (FR)
  • Université Paris Cité 2 , Paris, France
  • Université Côte d’Azur, INSERM, C3M 1 , Nice, France
  • Lyon 1 Université (FR)
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Necker-Enfants Malades (FR)
Corresponding author
Boyer, Laurent
ORCID
Venue
Journal of Experimental Medicine
Publisher
Rockefeller University Press
Published
2024-08-30
Volume
221
Issue
10
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
DOI
10.1084/jem.20231562
PMC
PMC11363864
OpenAlex
W4402049585
Semantic Scholar
233439add4bc4a2d0b640c5e0f5b069af36ef567
Cited by
12
References
41
Citations by year
2026: 6 · 2025: 6
FWCI
1.33
Type
journal article
Language
en
Open access
Licence
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Fondation pour la Recherche Médicale (EQU202403018053)
  • Agence Nationale de la Recherche (ANR-17-CE15-0001, ANR-22-CE15-0032, ANR-22-CE14-0003, ANR-11-LABX-0028-01, ANR-15-IDEX-01, ANR-10-INBS-09, ANR-19-P3IA-0002, ANR-23-IAHU-0007, ANR-10-IAHU-01, ANR-19-CE17-0012, ANR-21-CE17-0046, ANR-PRTS 2013)
  • E-Rare Joint Transnational Call for Proposals 2015 (EuroCID)
  • Association pour la Recherche sur le Cancer (RAC15014AAA)
  • Université Côte d’Azur
  • France Génomique National Infrastructure
  • Canceropôle PACA
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
Rac2, gain-of-function mutations, primary immunodeficiency, severe combined immunodeficiency, NLRP3 inflammasome, PAK1, IL-1β, IL-18, macrophages, autoinflammation, Rho GTPases, hematopoietic lineage
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Gain of Function Mutation, RAC2 GTP-Binding Protein, Animals, Humans, Macrophages, Signal Transduction, Interleukin-18, rac GTP-Binding Proteins, Mice, Interleukin-1beta, p21-Activated Kinases, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review